Portfolio

Backing highly innovative entrepreneurs developing disruptive technologies.

AdoRxLogoWeb

AdoRx Therapeutics

Edinburgh, United Kingdom

AdoRx is developing new modulators of the adenosine pathway for the treatment of cancer.

VIEW WEBSITE >>

APellisMaybe

Apellis Pharmaceuticals

Louisville, Kentucky

Apellis is developing therapeutics for the treatment of several major diseases, including the protection of red blood cells against immune destruction.

VIEW WEBSITE >>

Caldan Therapeutics

Edinburgh, United Kingdom

Caldan, a spin-out company from the Universities of Glasgow and Southern Denmark, is developing novel therapeutics targeting free fatty acid receptors for Type 2 Diabetes (T2D) and other potential indications.

VIEW WEBSITE >>

Clyde Biosciences

Glasgow, United Kingdom

Clyde Biosciences, a spin-out company from the University of Glasgow, has developed a pioneering technology to evaluate drug toxicity for pharmaceutical and biotechnology companies. Clyde Biosciences is developing the CellOPTIQ optical action potential assay to address major unmet needs in testing cardiotoxicity risk in both new and existing drugs.

VIEW WEBSITE >>

Confluence logo

Confluence Life Sciences

St. Louis, Missouri

Confluence Life Sciences, Inc. is a technology-based company focusing on rational drug design to identify proprietary, mechanistically novel drugs for cancer and chronic inflammatory diseases.

Acquired August 2017

EMISmall 3

Edinburgh Molecular Imaging

Edinburgh, United Kingdom

Edinburgh Molecular Imaging is developing a pioneering Optical Molecular Imaging (OMI) technology with the potential to address unmet needs in the diagnosis and monitoring of several major diseases.

VIEW WEBSITE >>

enterprise-therap

Enterprise Therapeutics

Brighton, United Kingdom

Enterprise Therapeutics is an early stage drug discovery company formed in May 2014. Its founders have significant expertise in drug discovery, respiratory biology and ion channel pharmacology.  The company benefits from a close working relationship with the School of Life Sciences at the University of Sussex.

VIEW WEBSITE >>

Eternygen

Berlin, Germany

Eternygen was founded in June 2012 to focus on the research, development and marketing of inhibitors of NaCT, a novel target which is also known as INDY (I am Not Dead Yet), for the treatment of dietary-related metabolic diseases.

VIEW WEBSITE >>

IGEM Logo Square Illustrator new

IGEM Therapeutics

London, United Kingdom

IGEM Therapeutics a spin-out from King’s College London with a world leading position in the development of IgE-based antibody therapeutics for the treatment of cancer.

VIEW WEBSITE >>

Harpoon Medical, Inc.

Harpoon Medical, Inc.

Baltimore, Maryland

Harpoon Medical, Inc. is a development stage medical device company located in Maryland commercializing a minimally invasive, image-guided surgical tool for beating heart mitral valve repair.

Acquired December 2017

MironidLogoSmall

Mironid

Glasgow, United Kingdom

Mironid is developing proprietary drug candidates that modulate the activity of key phosphodiesterase 4 (PDE4) enzymes in chronic inflammatory and degenerative kidney diseases.

VIEW WEBSITE >>

NodTheraLogo

NodThera

Cambridge, United Kingdom

NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation.

VIEW WEBSITE >>

SIRAKOSS logo

SIRAKOSS

Aberdeen, United Kingdom

SIRAKOSS was formed to October 2010 and following commercial validation the technology was spun out of the University of Aberdeen in May 2011. The company successfully completed proof of concept in 2012 and raised Seed Fund investment in 2013.

VIEW WEBSITE >>

TopasLogo2016small

Topas Therapeutics

Hamburg, Germany

Topas is an early stage therapeutics company using ground breaking nanoparticle technology to target autoimmune and inflammatory diseases via the induction of antigen specific immune tolerance in the liver.

VIEW WEBSITE >>